Drugs / Donor Natural Killer (NK) cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01478074 | Nov 2011 → Oct 2013 | acute myeloid leukemia | Altor BioScience | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00823524 | Jan 2009 → Feb 2013 | cancer of unknown primary site, central nervous system neoplasm, leukemia, lymphoproliferative syndrome +4 | Asan Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | donor natural killer (NK) cells | “Phase I: Patients receive an infusion of donor natural killer (NK) cells on days 18 and 21.” NCT00823524 ↗ |
| Action | Deplete | “Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.” NCT00823524 ↗ |
| Modality | Cell therapy | “donor natural killer (NK) cell infusion” NCT00823524 ↗ |